Literature DB >> 33687618

The cost of chemotherapy administration: a systematic review and meta-analysis.

Gursharan K Sohi1, Jordan Levy2, Victoria Delibasic1, Laura E Davis1, Alyson L Mahar3, Elmira Amirazodi1, Craig C Earle4, Julie Hallet2, Ahmed Hammad5, Rajan Shah1, Nicole Mittmann6, Natalie G Coburn7.   

Abstract

PURPOSE: Cancer treatment is a significant driver of healthcare costs worldwide, however, the economic impact of treating patients with anti-neoplastic agents is poorly elucidated. We conducted a systematic review and meta-analysis to estimate the direct costs associated with administering intravenous chemotherapy in an outpatient setting.
METHODS: We systematically searched four databases from 2010 to present and extracted hourly administration costs and the respective components of each estimate. Separate analyses were conducted of Canadian and United States (US) studies, respectively, to address a priori hypotheses regarding heterogeneity amongst estimates. The Drummond checklist was used to assess risk-of-bias. Data were summarized using medians with interquartile ranges and five outliers were identified; costs were presented in 2019 USD.
RESULTS: Forty-four studies were analyzed, including sub-analyses of 19 US and seven Canadian studies. 26/44 studies were of moderate-high quality. When components of administration cost were evaluated, physician costs were reported most frequently (24 studies), followed by lab tests (13) and overhead costs (9). The median estimate (excluding outliers) was $142/hour (IQR = $103-166). The median administration cost in the US was $149/hour (IQR = $118-158), and was $128/hour (IQR = $102-137) in Canada.
CONCLUSIONS: There is currently a paucity of literature addressing the costs of chemotherapy administration, and existing studies utilize a patchwork of reporting methodologies which renders direct comparison challenging. Our results demonstrate that the cost of administering chemotherapy is approximately $125-150/hour, globally. This value is dependent upon the region of analysis, inclusiveness of cost subcomponents as well as the methodology used to estimate unit prices, as described here.

Entities:  

Keywords:  Cancer; Chemotherapy; Cost; Healthcare systems; Medico-economic

Year:  2021        PMID: 33687618     DOI: 10.1007/s10198-021-01278-0

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  50 in total

Review 1.  Value-Based Calculators in Cancer: Current State and Challenges.

Authors:  Chadi Nabhan; Bruce A Feinberg
Journal:  J Oncol Pract       Date:  2017-06-15       Impact factor: 3.840

2.  Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party.

Authors:  M F Drummond; T O Jefferson
Journal:  BMJ       Date:  1996-08-03

3.  Cost-effectiveness of treatment strategies for pancreatic head adenocarcinoma and potential opportunities for improvement.

Authors:  Daniel E Abbott; Ryan P Merkow; Scott B Cantor; Jason B Fleming; Gauri R Varadhachary; Christopher Crane; David J Bentrem; Karl Y Bilimoria
Journal:  Ann Surg Oncol       Date:  2012-09-11       Impact factor: 5.344

4.  Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.

Authors:  V Babashov; M A Begen; J Mangel; G S Zaric
Journal:  Curr Oncol       Date:  2017-02-27       Impact factor: 3.677

5.  Promoting continence--continence advice.

Authors:  A Turner
Journal:  Geriatr Nurs Home Care       Date:  1989-03

Review 6.  Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.

Authors:  Hamzeh Albaba; Charles Lim; Natasha B Leighl
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

7.  Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies.

Authors:  F Awan; S T Kochuparambil; D E Falconer; A Cumpston; S Leadmon; K Watkins; D Deremer; A Jillella; M Craig; M Hamadani
Journal:  Bone Marrow Transplant       Date:  2013-04-15       Impact factor: 5.483

8.  The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma.

Authors:  Daniel E Abbott; Ching-Wei David Tzeng; Ryan P Merkow; Scott B Cantor; George J Chang; Matthew Harold Katz; David J Bentrem; Karl Y Bilimoria; Christopher H Crane; Gauri R Varadhachary; James L Abbruzzese; Robert A Wolff; Jeffrey E Lee; Douglas B Evans; Jason B Fleming
Journal:  Ann Surg Oncol       Date:  2013-02-10       Impact factor: 5.344

9.  Cost-effectiveness of pazopanib in advanced soft tissue sarcoma in the United kingdom.

Authors:  Jordan Amdahl; Stephanie C Manson; Robert Isbell; Ayman Chit; Jose Diaz; Lily Lewis; Thomas E Delea
Journal:  Sarcoma       Date:  2014-06-12

Review 10.  Economic Analysis of Children's Surgical Care in Low- and Middle-Income Countries: A Systematic Review and Analysis.

Authors:  Anthony T Saxton; Dan Poenaru; Doruk Ozgediz; Emmanuel A Ameh; Diana Farmer; Emily R Smith; Henry E Rice
Journal:  PLoS One       Date:  2016-10-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.